Catalyst Capital Advisors LLC Gilead Sciences, Inc. Transaction History

Catalyst Capital Advisors LLC

$4.41 Billion
Q3 2024

A detailed history of Catalyst Capital Advisors LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Catalyst Capital Advisors LLC holds 962 shares of GILD stock, worth $86,762. This represents 0.0% of its overall portfolio holdings.

Number of Shares

962

Previous 1,214 20.76%

Holding current value

$86,762

Previous $83,000 3.61%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 30, 2024	SELL	$66.59 - $83.99 $16,780 - $21,165	-252 Reduced 20.76%	962 $80,000
Q2 2024 Jul 25, 2024	BUY	$63.15 - $72.88 $2,526 - $2,915	40 Added 3.41%	1,214 $83,000
Q1 2024 Apr 24, 2024	BUY	$71.58 - $87.29 $286 - $349	4 Added 0.34%	1,174 $85,000
Q4 2023 Feb 14, 2024	BUY	$73.27 - $83.09 $18,097 - $20,523	247 Added 26.76%	1,170 $94,000
Q3 2023 Nov 09, 2023	BUY	$73.94 - $80.67 $17,375 - $18,957	235 Added 34.16%	923 $69,000
Q2 2023 Aug 08, 2023	SELL	$76.01 - $86.7 $2,660 - $3,034	-35 Reduced 4.84%	688 $53,000
Q1 2023 May 12, 2023	SELL	$77.31 - $88.08 $19,791 - $22,548	-256 Reduced 26.15%	723 $59,000
Q4 2022 Feb 07, 2023	SELL	$62.32 - $89.47 $1,308 - $1,878	-21 Reduced 2.1%	979 $84,000
Q3 2022 Nov 08, 2022	SELL	$59.54 - $68.01 $59 - $68	-1 Reduced 0.1%	1,000 $62,000
Q2 2022 Aug 09, 2022	SELL	$57.72 - $65.01 $145,108 - $163,435	-2,514 Reduced 71.52%	1,001 $62,000
Q1 2022 May 10, 2022	SELL	$57.92 - $72.58 $23,399 - $29,322	-404 Reduced 10.31%	3,515 $209,000
Q4 2021 Feb 10, 2022	SELL	$64.88 - $73.64 $3,827 - $4,344	-59 Reduced 1.48%	3,919 $284,000
Q3 2021 Nov 09, 2021	SELL	$67.69 - $73.03 $1,218 - $1,314	-18 Reduced 0.45%	3,978 $278,000
Q2 2021 Aug 06, 2021	BUY	$63.47 - $69.35 $206,404 - $225,526	3,252 Added 437.1%	3,996 $275,000
Q1 2021 May 10, 2021	SELL	$60.0 - $68.46 $8,340 - $9,515	-139 Reduced 15.74%	744 $48,000
Q4 2020 Feb 05, 2021	SELL	$56.65 - $64.55 $119,928 - $136,652	-2,117 Reduced 70.57%	883 $51,000
Q3 2020 Nov 05, 2020	SELL	$62.1 - $78.08 $93,150 - $117,120	-1,500 Reduced 33.33%	3,000 $190,000
Q2 2020 Aug 10, 2020	SELL	$72.34 - $84.0 $679,996 - $789,600	-9,400 Reduced 67.63%	4,500 $346,000
Q1 2020 May 12, 2020	BUY	$62.63 - $80.22 $870,557 - $1.12 Million	13,900 New	13,900 $1.04 Million
Q2 2018 Aug 07, 2018	SELL	$64.88 - $75.68 $3.28 Million - $3.82 Million	-50,514 Closed	0 $0
Q1 2018 May 18, 2018	BUY	$72.84 - $88.8 $230,538 - $281,052	3,165 Added 6.68%	50,514 $3.81 Million
Q4 2017 Feb 08, 2018	SELL	$71.15 - $83.52 $92,850 - $108,993	-1,305 Reduced 2.68%	47,349 $3.39 Million
Q3 2017 Nov 08, 2017	BUY	$72.11 - $85.47 $3.51 Million - $4.16 Million	48,654	48,654 $3.94 Million

Others Institutions Holding GILD

# of Institutions

1,923

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Catalyst Capital Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Catalyst Capital Advisors LLC with notifications on news.

Account

Catalyst Capital Advisors LLC Gilead Sciences, Inc. Transaction History